However, the lesion-specific delivery of the NgR(310)-Fc protein to all disseminated lesion sites in the context of MS pathology is such an enormous challenge due to pathological heterogeneity and a more targeted therapeutic delivery requires elucidation. Here, RTN4R is linked to myeloid sarcoma.